Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity.

ABSTRACT:

Background

Doxorubicin and other anthracyclines are crucial cancer treatment drugs. However, they are associated with significant cardiotoxicity, severely affecting patient care and limiting dosage and usage. Previous studies have shown that low carbon monoxide (CO) concentrations protect against doxorubicin toxicity. However, traditional methods of CO delivery pose complex challenges for daily administration, such as dosing and toxicity. To address these challenges, we developed a novel oral liquid drug product containing CO (HBI-002) that can be easily self-administered by patients with cancer undergoing doxorubicin treatment, resulting in CO being delivered through the upper gastrointestinal tract.

Methods and results

HBI-002 was tested in a murine model of doxorubicin ca

SUBMITTER: Alves de Souza RW 

PROVIDER: S-EPMC11179858 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature